Kongming Wu

42PUBLICATIONS
15CO-AUTHORS
Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Jun 23, 2026
From M7824 to SHR-1701: lessons for dual PD-L1/TGF-β targeting.

|Feb 09, 2026
Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response.

Ming Yi, Tianye Li, Yinhui Gu

|Jan 13, 2025
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy.

Qinglong Ma, Wenyang Zhang, Kongming Wu

|Sep 20, 2024
Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti-TGF-β/PD-L1 Bispecific Antibody.

Ming Yi, Tianye Li, Mengke Niu

|Jun 05, 2024
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors.

Yuze Wu, Ming Yi, Mengke Niu

|Dec 02, 2022
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.

Ming Yi, Yuze Wu, Mengke Niu

Pageof 7

Frequent Collaborators

2 joint publications

Ming Yi

1 joint publications

Alejandra Bravo

1 joint publications

Kaiyu Liu

1 joint publications

Anping Li